NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$10.73−0.41 (-3.68%)
Close on Nov 18, 2026Market cap $1.25BP/E –Yield –
NovoCure operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
NovoCure's operating income for the twelve months ending Sep 30, 2026 was -$124.55M. For fiscal 2025 it was -$153.80M. The highest annual figure on record is $30.40M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$153.80M | – |
| FY2024 | Dec 31, 2024 | -$170.50M | – |
| FY2023 | Dec 31, 2023 | -$232.87M | – |
| FY2022 | Dec 31, 2022 | -$89.52M | – |
| FY2021 | Dec 31, 2021 | -$44.33M | -245.8% |
| FY2020 | Dec 31, 2020 | $30.40M | – |
| FY2019 | Dec 31, 2019 | -$914.00K | – |
| FY2018 | Dec 31, 2018 | -$33.67M | – |
| FY2017 | Dec 31, 2017 | -$39.33M | – |
| FY2016 | Dec 31, 2016 | -$115.32M | – |
| FY2015 | Dec 31, 2015 | -$104.00M | – |
| FY2014 | Dec 31, 2014 | -$80.16M | – |
| FY2013 | Dec 31, 2013 | -$64.46M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.17M | – |
| Q2 FY2026 | Jun 30, 2026 | -$10.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$67.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$40.39M | – |
| Q3 FY2025 | Sep 30, 2025 | -$36.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$39.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$63.30M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$41.52M | – |
| Q4 FY2023 | Dec 31, 2023 | -$51.72M | – |
| Q3 FY2023 | Sep 30, 2023 | -$58.25M | – |
| Q2 FY2023 | Jun 30, 2023 | -$62.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$60.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$42.98M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$806.00K | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.40M | -293.5% |
| Q3 FY2021 | Sep 30, 2021 | -$8.55M | -156.9% |
| Q2 FY2021 | Jun 30, 2021 | -$12.30M | -284.4% |
| Q1 FY2021 | Mar 31, 2021 | -$88.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $12.09M | +7803.3% |
| Q3 FY2020 | Sep 30, 2020 | $15.02M | +289.7% |
| Q2 FY2020 | Jun 30, 2020 | $6.67M | +457.5% |
| Q1 FY2020 | Mar 31, 2020 | -$3.38M | – |
| Q4 FY2019 | Dec 31, 2019 | $153.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $3.86M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.66M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.25M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$12.68M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.51M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.92M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.53M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.37M | – |
| Q4 FY2016 | Dec 31, 2016 | -$17.88M | – |
See a number that looks wrong?